10 Affordable Blue Chip Stocks To Buy Now

In this article, we discuss the 10 affordable blue chip stocks to buy now. If you want to skip our detailed analysis of blue chip stocks and the current market situation, go directly to 5 Affordable Blue Chip Stocks To Buy Now.

The stock market is not easy picking right now even for the most experienced investors on Wall Street. The S&P500, down 21.74% in the year so far, fell further into bear market territory, sliding for the fifth straight day on Tuesday. The 10-year Treasury yield rose to its highest level since April 2011, showing an increment of 11 basis points to touch 3.483%. The 2-year yield gained approximately 16 basis points to reach 3.437%, a 15-year high. Yields move in the opposite direction to stock prices, and this two-way battering in the stock market has exacerbated as investors prepare for the Fed’s interest rates hike this week, with many betting on a massive 75 basis points increase. This comes as experts fear inflation hasn’t topped, with CPI (consumer price index) figures for May showing year-on-year growth of 8.6%, the biggest increase in almost 41 years. All this comes on top of soaring energy prices, and geopolitical tensions emanating from the Russia-Ukraine crisis dampening investor sentiment around the world.

Still, the stock market needs investors, and investors need high quality, affordable stocks to put their money into. That’s why, we’ve prepared a list of the 10 affordable blue chip stocks to buy now, which includes names such as The Coca-Cola Company (NYSE:KO), Bank of America Corporation (NYSE:BAC), and Shell plc (NYSE:SHEL), along with others mentioned below. Blue chip stocks have a solid track record of posting market-beating returns and their huge market capitalizations make them less susceptible to the most violent throes of market volatility. These stocks also often make stable dividend payments, making their ownership a safe bet in the most stressed of economic climates.

Photo by Kaleidico on Unsplash

Our Methodology

We picked 10 blue chip stocks which are well-positioned in the current market, and offer stable growth and earnings. To consider affordability, every stock in the following list is priced below $65. We have also provided hedge fund sentiment from Insider Monkey’s database of 912 hedge funds, to let our readers know what the hotshot money-managers of Wall Street are thinking about each stock.

Affordable Blue Chip Stocks To Buy Now

10. Barclays PLC (NYSE:BCS)

Number of Hedge Fund Holders: 16

Share Price (as of June 13): $7.74

Barclays PLC (NYSE:BCS) is one of the largest diversified banking firms in the world. The London-based company was founded in 1690, and offers a range of financial services including credit cards, retail banking, wholesale banking, wealth management, and investment management services.

On May 19, Keefe Bruyette analyst Edward Firth upgraded Barclays PLC (NYSE:BCS) to ‘Outperform’ from ‘Market Perform’ with a revised price target of 230 GBp, up from 210 GBp. The analyst noted that the bank’s performance is good, and the risk factors are already priced into the shares at current levels. As of June 13, Barclays PLC (NYSE:BCS) offers an impressive yield of 4.17%, and has paid shareholders dividend payouts since 1986.

For 2021, Barclays PLC (NYSE:BCS) posted an annual revenue of $30.17 billion, showing a 7.95% increase from its 2020 revenue of $27.94 billion. The firm reported a revenue of $8.1 billion for Q1 2022, above estimates by $832.7 million.

Banks tend to do well during periods of inflation and rising interest rates, and investors were understandably seen snapping up on Barclays PLC (NYSE:BCS) shares. At the close of March, 16 hedge funds were stakeholders in the company, as compared to 11 hedge funds a quarter earlier. The total value of Q1 hedge fund holdings stood at $121.4 million. Barclays PLC’s (NYSE:BCS) largest shareholder in the first quarter was Masters Capital Management with a $39.5 million stake, up 25% from the previous quarter.

Just like The Coca-Cola Company (NYSE:KO), Bank of America Corporation (NYSE:BAC), and Shell plc (NYSE:SHEL), Barclays PLC (NYSE:BCS) ranks as one of the best, and most affordable blue chip investments to make today.

9. BHP Group (NYSE:BHP)

Number of Hedge Fund Holders: 19

Share Price (as of June 13): $61.31

BHP Group (NYSE:BHP) deals in the mining, production and supply of oil, natural gas, iron ore, uranium, gold and coal products around the world. The firm operates in more than 90 countries around the world including United States, Canada, Chile, and Australia, where it is headquartered. BHP Group (NYSE:BHP) offers an impressive yet sustainable yield of 11.51% as of June 13, and has grown its dividend payments for 5 years in a row.

BHP Group’s (NYSE:BHP) annual revenue for 2021 stood at $60.8 billion, representing a jump of 41.66% from its 2020 revenue of $42.9 billion. As of June 13, the company shares have registered an uptick of 17.39% in the last 6 months, and 12.99% so far in 2022.

Goldman Sachs analyst Paul Young on June 1 reinstated coverage of BHP Group (NYSE:BHP) with a ‘Buy’ rating and a price target of A$51.20. The analyst cited an attractive valuation and upside from copper growth, following the merger of BHP’s oil and gas portfolio with Woodside to establish an independent energy company. Young notes that the company has traded at a premium to global mining peers over the last decade, and he expects this trend to persist.

As of the end of the first quarter, 19 hedge funds were bullish on BHP Group (NYSE:BHP), with combined stakes worth $2.24 billion. This is in comparison to 25 hedge funds in the previous quarter. Fisher Asset Management was the firm’s largest Q1 shareholder, with a $1.3 billion stake consisting of 16.9 million shares, showing an increase in stake of 117% over the previous quarter.

Harding Loevner, an investment management firm, mentioned BHP Group (NYSE:BHP) in its Q1 2021 investor letter. Here’s what the fund said:

“Our purchase of Australian mining company BHP is an example of a quality company at a moderate valuation that should deliver attractive long-term returns. We believe the market has undervalued its enduring competitive advantage due to its low cost iron and copper mining operations which has allowed the company to deliver consistent profits and cash flows across the inevitable ups and downs of the global metals cycle. While the variability of commodity prices prevents BHP from scoring in the top ranks of measured quality, we are willing to bear some of that uncertainty in return for a more attractive valuation given the company’s strong business fundamentals.”

 8. American Airlines Group Inc. (NASDAQ:AAL)

Number of Hedge Fund Holders: 28

Share Price (as of June 13): $13.50

American Airlines Group Inc. (NASDAQ:AAL) is the world’s largest airline, considering the number of passengers carried and its fleet size, which stood at 865 aircrafts at the start of 2022. The Covid pandemic was perhaps the toughest on the airline industry, and American Airlines Group Inc. (NASDAQ:AAL) had to accept government aid after losing billions in a matter of months. With global travel accelerating back to pre-pandemic levels, a dominant name like American Airlines is well-poised in the market to post healthy gains.

On April 22, Argus analyst John Staszak upgraded American Airlines Group Inc. (NASDAQ:AAL) to ‘Buy’ from ‘Hold’, with a $24 price target. Staszak sees the stock as “favorably valued,” and expects it to benefit from an acceleration in business and international travel, as well as management’s efforts to reduce cost.

For Q1 2022, American Airlines Group Inc. (NASDAQ:AAL) disclosed EPS of -$2.32, exceeding estimates by $0.08. Revenue increased 122% in comparison to the year-ago quarter, standing at $8.9 billion and outperforming Street estimates by $77.16 million. 

28 hedge funds owned $474.8 million worth of positions in American Airlines Group Inc. (NASDAQ:AAL) at the close of Q1 2022, down from 30 hedge funds a quarter ago with $1.09 billion worth of stakes in the firm.

7. Shell plc (NYSE:SHEL)

Number of Hedge Fund Holders: 37

Share Price (as of June 13): $56.27

Shell plc (NYSE:SHEL) is a London-based energy company which deals in oil, natural gas, natural gas liquids, petrochemicals, and renewable energy services around the world. At $56.27, the company shares are trading at a significant discount in comparison to US rivals Exxon and Chevron.

The company’s revenue for the first quarter showed year-on-year growth of 51.3%, coming in at $84.2 billion, above analysts’ expectations by $39.36 billion. EPS of $2.40 also beat consensus estimates by $0.21. Shell plc (NYSE:SHEL) also pays a healthy dividend yield of 3.57% as of June 14.

On June 9, Credit Suisse analyst Amy Wong initiated coverage of Shell plc (NYSE:SHEL) with an ‘Outperform’ rating, along with a price target of 3,000 GBp. The energy company stands as Wong’s top pick in the European integrated energy sector, with the analyst noting that its strategic response to the energy transition is not reflected in the current share price. She stated that Shell’s energy transition strategy ranks as the most progressive in terms of decarbonization, and for generating strong cash flows that support its dividend payments in the near and medium term.

With a collective price tag of $5.63 billion, 37 hedge funds owned stakes in Shell plc (NYSE:SHEL) at the end of March. In contrast, 41 hedge funds were stakeholders in the energy firm a quarter ago. Fisher Asset Management initiated a $1.07 billion position in Shell plc (NYSE:SHEL) in the first quarter, making it the firm’s largest shareholder.

Grantham Mayo Van Otterloo & Co. LLC, an asset management firm, mentioned many stocks in its Q1 2022 investor letter, and Shell plc (NYSE:SHEL) was one of them. It said:

“The market is simply not valuing resource companies at reasonable levels given any plausible base case for how the world might play out, in our opinion. With oil prices up around 65% and natural gas prices up hundreds of percent since the beginning of 2020, Shell (NYSE:SHEL), a bellwether for the oil and gas industry, is more or less flat. With the movement in oil and gas prices, one would have expected Shell’s stock price to surge. It didn’t, however, leaving Shell at very attractive valuation levels. At commodity prices as of the end of the first quarter, Shell would be cranking out free cash flow yields of 22-23% for the next few years according to our models.”

6. AstraZeneca plc (NYSE:AZN)

Number of Hedge Fund Holders: 45

Share Price (as of June 13): $60.02

AstraZeneca plc (NYSE:AZN) ranks next on our list of affordable blue chip stocks to buy, along with names such as The Coca-Cola Company (NYSE:KO), Bank of America Corporation (NYSE:BAC), and Shell plc (NYSE:SHEL). The biopharmaceutical giant based in Cambridge, United Kingdom, makes and sells prescription medicines for a range of diseases. It made windfall profits from its Covid-19 vaccine, totaling $4 billion in 2021.

On May 24, Danske Bank analyst Caroline Baner initiated coverage of AstraZeneca plc (NYSE:AZN) with a ‘Buy’ rating and a 13,100 GBp price target. She sees “durable” growth drivers and visibility through 2030, and notes that AZN’s medicines in oncology, rare diseases and collaboration projects hold exclusivity in the US through 2030 and offer potentially significant sources of revenue.

Investors were seen loading up on AstraZeneca plc (NYSE:AZN) stock. At the end of March, 45 hedge funds were long on the company shares, as compared to 42 hedge funds a quarter earlier. With a $1.38 billion stake consisting of 20.84 million shares, Fisher Asset Management was the top shareholder of AstraZeneca plc (NYSE:AZN) in the first quarter of 2022.

For Q1 2022, AstraZeneca plc (NYSE:AZN) posted revenue of $11.39 billion, up 55.60% from the year-ago quarter and beating estimates by $423.24 million. As of June 14, the company offers a yield of 4.03%, and has paid a dividend since 1999.

Here is what Baron Funds, an investment management firm, had to say about AstraZeneca PLC (NYSE:AZN) in its Q1 2022 investor letter:

AstraZeneca PLC (NYSE:AZN) is a pharmaceutical company developing products across a range of indications including oncology, cardiovascular, and respiratory. AstraZeneca is widely recognized as having the best top-line and bottom- line growth profiles in the pharmaceutical space without a discernable patent cliff this decade. Given consistent new product outperformance (Calquence and Enhertu are recent examples), we expect continued share appreciation as AstraZeneca’s financials compound.”



Click to continue reading and see 5 Affordable Blue Chip Stocks To Buy Now.